Biological Drugs Market is Expanding at a CAGR of 10.10% Between 2014 and 2020

Press Release
The 2013 Biologics Report on states that many biopharmaceutical research companies in America are utilizing biological processes to create 907 medicines and vaccines aimed at more than 100 diseases. At present, several biological drugs are in the pipeline for auto-immune diseases, blood diseases, cancer-related conditions, and diabetes and cardiovascular diseases. The global biological drugs market is marked by robust R&D efforts. Companies in the global biological drugs market are investing millions to boost their R&D efforts to create revolutionary medications and therapies to target the most challenging disease.
Advancement in biomedical science holds a good promise for the development of novel biological products. This market trend will help the market expand significantly in the foreseeable future. The global biological drugs market is segmented on the basis of monoclonal antibody (mAb), vaccine, therapeutic protein, and geography.
The report on the global biological drugs market presents a detailed scenario of the challenges the market faces. The high cost associated with biological drugs will impede the market’s growth. Other factors such as the patent expiration of several blockbuster biological drugs, along with the growing risk of side effects of biological injectable medicines, will also suppress market growth.
The research study on the global biological drugs market presents a detailed scenario of the market restraints and delivers valuable recommendations on how players in the market can utilize these challenges to their advantage. A correlation, regression, and time-series analysis has been used to evaluate the key dynamics of the biological drugs industry.
Overview of the Global Biological Drugs Market
The global biological drugs market is driven by factors such as the growing prevalence of chronic conditions, increasing geriatric population, and accelerating regulatory compliance. In 2014, the global biological drugs market was worth US$161,056.5 million in 2014. With a 10.1% CAGR expected during the forecast period of 2014 to 2020, the global biological drugs market will reach a market value of US$287,139.7 million by 2020.
By therapeutic protein, the global biological drugs market is segmented into Enbrel, Neulasta, Lantus, Avonex, Rebif, NovoLog, Eylea, Neupogen, Betaseron, Levemir, Epogen, Aranesp, and Humalog. Enbrel is the dominating therapeutic protein sector in the global biological drugs market.
By mAb, the market is divided into Avastin, Rituxan, Remicade, Humira, Herceptin, and Lucentis. According to vaccine, the global biological drugs market is segmented into Ceravix, Varivax, Fluzoone, Gardasil, and Prenvar 13. Humira is the fastest growing mAb sector, while Prevnar 13 is the largest and fastest growing vaccine segment in the global biological drugs market.
In terms of geography, the global biological drugs market is divided into RoW, Europe, Asia, and North America. Presently, North America dominates the market, trailed by Europe due to its increasing adoption and use of biological products for the treatment of cancer, diabetes, and other fatal conditions.
Companies mentioned in the research report 
Some of the leading companies in the global biological drugs market are Roche, Amgen, and Novo Nordisk. Other notable companies in the market are Abbott Laboratories, Pfizer, Novartis, Eli Lilly, Bristol-Myers Squibb, Biogen, and Baxter.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: [email protected]



Related Articles